Article

Pembrolizumab Approved for First-Line Treatment of Unresectable or Metastatic Forms of Colorectal Cancer

According to a press release, this is the first single-agent, anti-PD-1 therapy approved in the first-line environment for this patient population.

The FDA has approved pembrolizumab (Keytruda, Merck) as a first-line treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

According to a press release, this is the first single-agent, anti-PD-1 therapy approved in the first-line environment for this patient population.

“Patients with unresectable or metastatic MSI-H colorectal cancer have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options,” said Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, in a statement.

The approval was based on the phase 3 Keynote-177 trial, which found that pembrolizumab significantly reduced the risk of disease progression or death by 40% compared with chemotherapy. The study enrolled 307 patients who were randomized 1:1 to receive 200 mg of pembrolizumab intravenously every 3 weeks, or an investigator’s choice of 2 chemotherapy regimens given intravenously every 2 weeks.

Patients who received pembrolizumab also had a more than double median progression-free survival compared with patients who received the standard-of-care chemotherapy (16.5 months vs 8.2 months).

Among the 153 patients with MSI-H or dMMR colorectal cancer who received pembrolizumab, the median duration of exposure to pembrolizumab was 11.1 months. Adverse events (AEs) were similar to those observed in 2799 patients with melanoma or non-small cell lung cancer who were treated with pembrolizumab as a single agent.

Immune-related AEs can occur with the drug, including pneumonitis, colitis, hepatitis, and nephritis and renal dysfunction. It can also cause severe or life-threatening infusion-related reactions.

“In patients who were treated with Keytruda and responded in the Keynote-177 trial, 43% of patients experienced a duration of response lasting 2 years or longer,” Diaz said in the release. “This approval helps address the unmet need to provide a new monotherapy treatment option for patients.”

REFERENCE

FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer [news release]. Merck; June 29, 2020. https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Patients-With-Unresectable-or-Metastatic-MSI-H-or-dMMR-Colorectal-Cancer/default.aspx. Accessed June 30, 2020.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards